DENTSPLY SIRONA Inc. (XRAY)
NEUTRALFundamental
51
Precio
$10.85
Capitalización Bursátil
$2.22B
Parte 1 · Cuánto vale la empresa
Resumen
Dentsply Sirona makes the equipment and consumable products dentists use every day: imaging systems, treatment chairs, drills and handpieces, plus the fillings, cements, orthodontic aligners and implants that go into patients' mouths. It sells almost entirely through the practices that treat patients, not directly to consumers, and its product groups span everything from a single filling to a full digital dental chair, mostly through independent distributors.
Cómo genera ingresos
Revenue comes from selling hardware and consumables to dental and orthodontic practices, largely through independent distributors such as Henry Schein and Patterson Companies rather than directly. Equipment like imaging systems and treatment chairs is a one-time or infrequent capital purchase; consumables like fillings, cements and aligner materials are repeat purchases tied to how many patients a practice treats. The distributor relationship means Dentsply Sirona's own sales force influences demand but rarely closes the final sale.
Qué impulsa la demanda
Moderadamente cíclicoRoutine dental care is fairly steady — people keep needing fillings and cleanings regardless of the economy — which supports demand for consumables. But the equipment side is more discretionary: practices can defer buying a new imaging system or chair in a weak economy, so Dentsply Sirona's results move with dental-practice capital spending as much as with patient volume.
Riesgos clave
- Distributor concentration — Two distributors, Henry Schein and Patterson, together account for around a fifth or more of net sales; losing or straining either relationship would disrupt how products reach practices.
- Product liability and recalls — Dental devices and materials carry inherent liability and recall risk; a quality issue with a widely used product could trigger a costly recall and reputational damage.
- Regulatory compliance across markets — The company operates under extensive and changing medical-device and product regulations in many countries, and failing to comply can bring civil or criminal penalties.
- Litigation and IP disputes — The company faces ongoing litigation risk, including securities claims, government investigations and patent disputes that can be costly to defend regardless of outcome.
Concentración de clientes
Los principales clientes representan el 13% de los ingresos
For 2025, distributor Henry Schein accounted for 13% of net sales and Patterson Companies for just under 10%; Dentsply Sirona sells most of its products through a small number of large distributors rather than directly to practices.
Los argumentos a favor
Buyers argue that Dentsply Sirona's product lines make it one of the few suppliers able to equip an entire dental practice, that recurring consumables sales cushion swings in equipment demand, and that recent segment reshuffling and cost cuts position the company to improve margins once dental capital spending recovers.
Los argumentos en contra
Sellers worry that the company competes in a fragmented dental-products market with no single dominant brand, that two distributors control a meaningful share of how its products reach practices, and that recent goodwill impairments in two of its segments signal the underlying businesses are worth less than once assumed.
Written by the editors, published on 18 de agosto de 2026
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance y Liquidez
Ingresos
$3.64B
Últimos 12 meses (hasta 30/6/2026)
Beneficio Neto
$-546M
Últimos 12 meses (hasta 30/6/2026)
Flujo de Caja Libre
$104M
Patrimonio Neto Total
$1.34B
Pasivo Total
$4.09B
Ratio de Liquidez
1.63
Cobertura de Intereses
3.41
Deuda/EBITDA
-
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$31.75
Precio Actual
$10.85
Margen de Seguridad
+65.8%
Rango de Valor Justo
$20.63 - $42.86
Métodos de Estimación
Métricas de Valoración
Ratio P/E
-
ROE
-44.7%
Ratio P/B
1.61
P/FCF
15.18
Margen Bruto
49.5%
ROIC
-6.1%
Radar de Rentabilidad
Value Creation (Economic Moat)
ROIC
-6.1%
WACC
6.1%
ROIC − WACC
-12.2 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Criterios de Análisis Fundamental
Superado (12)
- Gross Margin 49.5%
- P/FCF 15.18
- P/B Ratio 1.61
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- DCF valuation (Undervalued)
- Earnings Surprise avg 4.3%
- Share Dilution -1.9%
- Net Margin Trend -15.0% vs -25.9%
- Piotroski F-Score 6/9
Fallido (10)
- EPS shows upward trend
- Price CAGR -15.34%
- ROIC -6.1%
- Operating Margin -8.5%
- CapEx intensity
- Return on Tangible Assets
- Low reliance on intangibles
- ROE -39.8%
- Revenue Growth 5Y 2.0%
- Analyst Consensus 35% Buy
No disponible (5)
- Dividend Payout NaN%
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Señales mixtas: algunas áreas requieren atención
Calidad de los Beneficios
Baja calidad: investigue la contabilidad
Dilución de Acciones
Recomprando acciones. Favorable para el accionista
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Mr. Daniel T. Scavilla | President, CEO, Interim Principal Financial Officer & Director | 60 |
| Ms. Andrea L. Frohning | Senior VP & Chief Human Resources Officer | 55 |
| Mr. Robert Anthony Johnson | Senior VP & Chief Supply Chain Officer | 56 |
| Mr. Aldo M. Denti | Executive VP & Chief Commercial Officer | 57 |
| Mr. John C. Fortson | Executive VP & CFO | 58 |
| Mr. Kevin J. Czerney | Vice President & Chief Accounting Officer | 41 |
| Mr. Kevin Boyle | Senior VP & Chief Technology Officer | - |
| Wade Moody | Senior Manager of Investor Relations | - |
| Ms. Lindi Barton-Brobst | Senior VP & General Counsel | - |
| Ms. Emily P. Miner | Senior Vice President & Chief Quality Officer | - |
Riesgo de Auditoría
1
Riesgo del Consejo
3
Riesgo de Compensación
5
Riesgo de Derechos del Accionista
1
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Latest News
Recent headlines for XRAY, sourced from Markets Gazette.
- 3/13/2026POSITIVEIs Dentsply Sirona Stock a Buy After a Company Director Purchased 15,000 Shares?
A director at Dentsply Sirona Inc. has purchased 15,000 shares, signaling strong insider confidence in the dental technology firm. This move comes after a period of share price decline for the company, which is known for its robust recurring revenue streams. The insider transaction suggests that at least one key executive believes the stock is undervalued and poised for a recovery. Investors often view significant insider buying as a positive indicator, potentially preceding a turnaround or a period of sustained growth.
- 2/27/2026NEUTRALDENTSPLY SIRONA (XRAY) Q4 2025 Earnings Transcript
The market eagerly anticipates the release of the Q4 2025 earnings call transcript for DENTSPLY SIRONA (XRAY). While the specific content is not yet available, investor attention remains high for this crucial event. Quarterly earnings reports are fundamental for assessing a company's financial health, its performance against expectations, and the future outlook provided by management. Analysts and investors will be looking for insights into revenue, profitability, and, critically, guidance for upcoming periods. The current lack of details keeps the stock in a holding pattern, with potential significant movements once key information is disclosed. The transparency and data provided in these transcripts are essential for shaping investment decisions and understanding DENTSPLY SIRONA's strategic trajectory in the dental technology sector.
via Markets Gazette